NanoLogix

Devices & Diagnostics

NanoLogix readies FDA applications for rapid bacteria tests

Diagnostics company NanoLogix (OTCBB:NNLX) is preparing several U.S. Food and Drug Administration applications for its rapid bacteria-testing technology. NanoLogix said the applications will include results of tests that examined the company’s technology in detecting tuberculosis and Group B Streptococcus, according to a statement from the Hubbard, Ohio-based company. The company’s technology involves a proprietary water-permeable […]

Devices & Diagnostics

NanoLogix test shows promise in speeding up live tuberculosis detection

Diagnostics company NanoLogix (OTCBB:NNLX) reported that its rapid-bacteria-detection technology performed more quickly than the industry standard in the detection of live tuberculosis. Youngstown, Ohio-area NanoLogix said its BioNanoPore technology was able to detect live tuberculosis in four days, compared with a 21-day standard for live culture tuberculosis detection, according to a statement from the company. […]